Published Date:2021-04-19 Original Link:https://www.onenessbio.com/en/news_detail38_3.htm No 2 Date of announcement 2021/04/19 Time of announcement 19:32:01 Subject Oneness received approval by TFDA on the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma.      To which item it meets paragraph 10 Date of events 2021/04/19 Statement 1.Product:FB704A 2.Mass production...Read More